Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Enochian Biosciences Inc. stock logo
ENOB
Enochian Biosciences
$0.61
$0.39
$2.99
$40.80M1.09137,347 shs88,300 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$12.63
-0.6%
$12.69
$5.22
$27.38
$158.99M0.43145,863 shs75,083 shs
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
$5.66
+5.4%
$4.39
$1.97
$22.47
N/A1.41303,813 shs108,614 shs
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
$2.94
+1.4%
$1.36
$0.51
$3.06
$164.38M1.311.16 million shs1.84 million shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Enochian Biosciences Inc. stock logo
ENOB
Enochian Biosciences
0.00%0.00%0.00%0.00%0.00%
Lifevantage Corporation stock logo
LFVN
Lifevantage
0.00%-1.86%-4.68%-18.31%+88.79%
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
0.00%+1.25%+10.12%+58.99%-70.05%
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
0.00%+1.73%+332.23%+257.58%+131.50%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Enochian Biosciences Inc. stock logo
ENOB
Enochian Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.9823 of 5 stars
3.50.01.72.72.61.71.3
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
2.8518 of 5 stars
3.44.00.00.02.41.70.6
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
3.6131 of 5 stars
3.32.00.04.72.00.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Enochian Biosciences Inc. stock logo
ENOB
Enochian Biosciences
0.00
N/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.00
Buy$30.50141.49% Upside
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
2.71
Moderate Buy$33.83497.76% Upside
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
2.50
Moderate Buy$5.0070.07% Upside

Current Analyst Ratings Breakdown

Latest ENOB, SPRO, SLN, and LFVN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/13/2025
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$35.00
6/13/2025
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$75.00
5/9/2025
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSell ➝ Sell$4.00 ➝ $3.00
5/9/2025
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$45.00 ➝ $25.00
5/9/2025
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$55.00 ➝ $35.00
(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Enochian Biosciences Inc. stock logo
ENOB
Enochian Biosciences
N/AN/AN/AN/A$1.37 per shareN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$200.16M0.79$0.88 per share14.32$2.05 per share6.16
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
$43.26MN/AN/AN/A$4.48 per shareN/A
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
$47.98M3.43N/AN/A$0.85 per share3.46
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Enochian Biosciences Inc. stock logo
ENOB
Enochian Biosciences
-$113.43MN/A0.00N/AN/AN/A-154.69%-130.66%N/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$2.94M$0.6918.30N/A4.12%34.67%15.24%8/27/2025 (Estimated)
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
-$45.31M-$1.50N/AN/AN/A-260.55%-56.17%-33.96%8/15/2025 (Estimated)
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
-$68.57M-$1.28N/AN/AN/A-156.48%-123.50%-58.96%8/4/2025 (Estimated)

Latest ENOB, SPRO, SLN, and LFVN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
-$0.55-$0.25+$0.30-$0.25$11.00 million$5.87 million
5/8/2025Q1 2025
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
-$0.18-$0.60-$0.42-$0.60$3.58 million$0.14 million
5/6/2025Q3 2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.16$0.26+$0.10$0.26$60.99 million$58.44 million
3/27/2025Q4 2024
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
-$0.35-$0.38-$0.03-$0.38$12.40 million$15.04 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Enochian Biosciences Inc. stock logo
ENOB
Enochian Biosciences
N/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.181.43%N/A26.09%3 Years
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
N/AN/AN/AN/AN/A
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
N/AN/AN/AN/AN/A

Latest ENOB, SPRO, SLN, and LFVN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
quarterly$0.04501.5%5/30/20255/30/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Enochian Biosciences Inc. stock logo
ENOB
Enochian Biosciences
N/A
0.33
0.33
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.66
0.98
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
N/A
8.81
8.81
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
N/A
2.56
2.56

Institutional Ownership

CompanyInstitutional Ownership
Enochian Biosciences Inc. stock logo
ENOB
Enochian Biosciences
7.16%
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
98.73%
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
25.60%

Insider Ownership

CompanyInsider Ownership
Enochian Biosciences Inc. stock logo
ENOB
Enochian Biosciences
21.72%
Lifevantage Corporation stock logo
LFVN
Lifevantage
20.65%
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
4.10%
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
5.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Enochian Biosciences Inc. stock logo
ENOB
Enochian Biosciences
2258.28 million45.63 millionNot Optionable
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.59 million9.99 millionOptionable
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
100N/AN/ANot Optionable
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
15055.91 million52.84 millionOptionable

Recent News About These Companies

Spero Therapeutics, Inc. stock logo
Best Penny Stocks To Watch Today - May 28th

New MarketBeat Followers Over Time

Media Sentiment Over Time

Enochian Biosciences stock logo

Enochian Biosciences NASDAQ:ENOB

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer. The company's product pipeline includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a gene therapy curative treatment for HBV. It develops ENOB-DC-11, an allogeneic dendritic cell therapeutic vaccine for solid tumors; ENOB-DC-12-XX, allogeneic dendritic cell therapeutic vaccine for other solid tumors; and ENOB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. Enochian Biosciences, Inc. has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was incorporated in 2017 and is headquartered in Los Angeles, California.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$12.63 -0.07 (-0.55%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$12.89 +0.26 (+2.05%)
As of 06/18/2025 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

Silence Therapeutics stock logo

Silence Therapeutics NASDAQ:SLN

$5.66 +0.29 (+5.40%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$5.61 -0.05 (-0.87%)
As of 06/18/2025 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

Spero Therapeutics stock logo

Spero Therapeutics NASDAQ:SPRO

$2.94 +0.04 (+1.38%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$2.92 -0.02 (-0.68%)
As of 06/18/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.